biotech · SARS-CoV-2 Infection · Breast Cancer
Henlius USA
Shanghai Henlius Biotech
Shanghai Henlius Biotech is a biotech organization headquartered in CN. Primary therapeutic focus areas include SARS-CoV-2 Infection, Breast Cancer, HLX07, nsqNSCLC, High EGFR Expression. NovaPharmaNews links 3 clinical
Milpitas, USA HQ
2010 Founded
45 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Milpitas, USA
- Founded
- 2010
- Employees
- 45
- Programs
- 3
- Drugs
- 4
- Patents
- 0
HLX07+carboplatin+pemetrexed
Phase 2 · small molecule · HLX07, nsqNSCLC, High EGFR Expression
HLX07+carboplatin+pemetrexed for HLX07, nsqNSCLC, High EGFR Expression is a Phase 2 program (small_molecule) at Shanghai Henlius Biotech with 1 ClinicalTrials.gov record(s).
Internal code HLX07-nsqNSCLC201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Henlius Biotech
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- HLX07, nsqNSCLC, High EGFR Expression
- Status
- active
- Trials
- 1